Collplant Biotechnologies Ltd - ESG Rating & Company Profile powered by AI
Full ESG analysis of Collplant Biotechnologies Ltd can be accessed by logging in. This Disclosure rating includes seventeen UN SDGs including: 'Affordable & Clean Energy', 'Sustainable Cities & Communities' and 'Peace, Justice & Strong Institutions'. This Sustainability rating for Collplant Biotechnologies Ltd represents the company's transparency towards the UN SDGs.
Collplant Biotechnologies Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.4; made up of an environmental score of 2.7, social score of 6.4 and governance score of 4.0.
4.4
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
868 | Trevena Inc | 4.5 | High |
868 | Urogen Pharma Ltd | 4.5 | High |
910 | Collplant Biotechnologies Ltd | 4.4 | High |
910 | CanBas Co Ltd | 4.4 | High |
910 | CNS Pharmaceuticals Inc | 4.4 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Collplant Biotechnologies Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Collplant Biotechnologies Ltd disclose current and historical energy intensity?
Does Collplant Biotechnologies Ltd report the average age of the workforce?
Does Collplant Biotechnologies Ltd reference operational or capital allocation in relation to climate change?
Does Collplant Biotechnologies Ltd disclose its ethnicity pay gap?
Does Collplant Biotechnologies Ltd disclose cybersecurity risks?
Does Collplant Biotechnologies Ltd offer flexible work?
Does Collplant Biotechnologies Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Collplant Biotechnologies Ltd disclose the number of employees in R&D functions?
Does Collplant Biotechnologies Ltd conduct supply chain audits?
Does Collplant Biotechnologies Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Collplant Biotechnologies Ltd conduct 360 degree staff reviews?
Does Collplant Biotechnologies Ltd disclose the individual responsible for D&I?
Does Collplant Biotechnologies Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Collplant Biotechnologies Ltd disclose current and / or historical scope 2 emissions?
Does Collplant Biotechnologies Ltd disclose water use targets?
Does Collplant Biotechnologies Ltd have careers partnerships with academic institutions?
Did Collplant Biotechnologies Ltd have a product recall in the last two years?
Does Collplant Biotechnologies Ltd disclose incidents of discrimination?
Does Collplant Biotechnologies Ltd allow for Work Councils/Collective Agreements to be formed?
Has Collplant Biotechnologies Ltd issued a profit warning in the past 24 months?
Does Collplant Biotechnologies Ltd disclose parental leave metrics?
Does Collplant Biotechnologies Ltd disclose climate scenario or pathway analysis?
Does Collplant Biotechnologies Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Collplant Biotechnologies Ltd disclose the pay ratio of women to men?
Does Collplant Biotechnologies Ltd support suppliers with sustainability related research and development?
Does Collplant Biotechnologies Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Collplant Biotechnologies Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Collplant Biotechnologies Ltd involved in embryonic stem cell research?
Does Collplant Biotechnologies Ltd disclose GHG and Air Emissions intensity?
Does Collplant Biotechnologies Ltd disclose its waste policy?
Does Collplant Biotechnologies Ltd report according to TCFD requirements?
Does Collplant Biotechnologies Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Collplant Biotechnologies Ltd disclose energy use targets?
Does Collplant Biotechnologies Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Collplant Biotechnologies Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Collplant Biotechnologies Ltd
These potential risks are based on the size, segment and geographies of the company.
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.